At a 52-week low, is the British American Tobacco share price too cheap to ignore?

The British American Tobacco share price is at its lowest point this year. But does a 9% dividend yield justify buying a stock in a declining industry?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

happy senior couple using a laptop in their living room to look at their financial budgets

Image source: Getty Images

Anyone who bought British American Tobacco (LSE:BATS) shares in the last 12 months is sitting on an unrealised loss (unless they sold them already). The stock is at a 52-week low.

At £24.86, the share price is back where it was in 2011. But is a 9% dividend yield from a company with increasing revenues, margins and profits too good to ignore?

Fundamentals

At first sight, the company’s fundamentals look good. At a basic level, the firm makes a product that’s cheap, addictive, and sells it to a customer base that tends to be loyal to its preferred brands.

Over the last decade, this has resulted in some impressive numbers. Revenues have grown at an average of 6% per year, margins have expanded, and the dividend has gone from £1.38 to £2.18.

This looks difficult to argue with. But beneath the surface, there are some red flags for investors to be aware of. 

First, a closer look at the revenue line shows something interesting. While 10-year growth averages 6%, over the last five years, sales have only increased by an average of 2.5% per year.

On top of this, the company’s growth has been financed by equity. As a result, the number of shares outstanding is 10% higher than it was a decade ago, diluting the effect of that growth.

Neither of these is positive and investors will want to keep an eye on these going forward. Both might go some way to explaining why the stock has been steadily moving lower since 2017.

Outlook

Recent issues notwithstanding, the company has an enviable record of growth. And at a price-to-earnings (P/E) ratio of 6, it looks cheap relative to the rest of the FTSE 100.

Investors today aren’t buying a share of the company’s historic profits, though. Rather, they’re buying a stake in the company’s future – so what does that future look like?

Like most tobacco companies, British American is hoping the number of smokers doesn’t decline by too much. But this looks unlikely to me.

Almost 70% of the company’s sales come from the US (45%) and Europe (23%). But the demographics in these areas don’t look favourable for the future of smoking.

First, the proportion of smokers in both regions is declining. This is true across the globe, but it’s especially true in developed economies, such as Europe and the US.

Second, the birth rates in both regions are low. This means that the proportion of people smoking is going down and the population as a whole is declining. Together, I think these create a powerful headwind for the business.

Foolish takeaways

With British American Tobacco, the cash it generates in the short term might justify an investment at today’s prices, despite some long-term headwinds. But that’s not my style as an investor.

When I invest, I look for stocks that I can buy and hold for the long term. This means companies that are going to be in a strong position 30 years from now.

British American Tobacco doesn’t fit that profile, so it’s not a stock for me. But I do accept that there’s not been a better buying opportunity here since 2011.

Stephen Wright has no position in any of the shares mentioned. The Motley Fool UK has recommended British American Tobacco P.l.c. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »